RN Mobile Menu


Rheumatology Network

Mortality Risk in RA Patients on TNF-α Inhibitors

Tumor necrosis factor-a inhibitors are the most widely used biologic therapy in rheumatoid arthritis. A new study shows that TNF-a inhibitors are not associated with increased mortality in RA patients.
(Photo credit, ©SherryYatesYoungShuttestock)

Recent Content

Controlling depressive symptoms in patients with early inflammatory polyarthritis could affect disease outcomes, researchers suggest.

Study shows increased cardiovascular disease risk in RA. Screening and treatment recommended.

In rheumatoid arthritis there is an ongoing debate about what to do when Methotrexate fails. Physicians typically have two choices.

Biologics can improve the quality of life for RA patients, but side effects remain a problem, especially for RA patients with co-morbidities.

B-cells that are active in lupus may also play a role in Sjögren’s syndrome. A new study finds that the same B-cell depleter drug, belimumab (Benlysta) approved for lupus, may also benefit Sjögren’s patients.

The management of a 22-year-old woman with ocular sarcoidosis.

Social stressors, such as being treated poorly in a doctor’s office, can lead to negative disease outcomes, particularly among black women with lupus, a new study shows.

By clicking Accept, you agree to become a member of the UBM Medica Community.